X

Trial Profile

'Switching anticoagulant management from a VKA to a NOAC-based treatment strategy in frail elderly patients with atrial fibrillation (FRAIL-AF study)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acenocoumarol (Primary) ; Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Phenprocoumon (Primary) ; Rivaroxaban (Primary)
Indications Embolism and thrombosis
Focus Adverse reactions
Acronyms FRAIL-AF study

Most Recent Events

15 Sep 2023 Status changed from discontinued to recruiting.
05 Sep 2023 According to a Cadrenal Therapeutics media release, data from this study was presented at European Society of Cardiology Congress (ESC) in Amsterdam.
19 Sep 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com